Mike Trower

Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1)

James A. Simon, Richard A. Anderson, Elizabeth Ballantyne et al. · Menopause The Journal of The North American Menopause Society · 2023 · 81 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal women: a placebo-controlled, randomized trial

Mike Trower, Richard A. Anderson, Elizabeth Ballantyne et al. · Menopause The Journal of The North American Menopause Society · 2020 · 76 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Elinzanetant (NT-814), a Neurokinin 1,3 Receptor Antagonist, Reduces Estradiol and Progesterone in Healthy Women

Steve Pawsey, Edouard Gregory Mills, Elizabeth Ballantyne et al. · The Journal of Clinical Endocrinology & Metabolism · 2021 · 32 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Neurokinin-1 antagonist orvepitant for EGFRI-induced pruritus in patients with cancer: a randomised, placebo-controlled phase II trial

Bruno Vincenzi, Mike Trower, Ajay Duggal et al. · BMJ Open · 2020 · 13 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

OR11-03 NT-814, a Non-Hormonal Dual Neurokinin 1,3 Receptor Antagonist Markedly Improves Vasomotor Symptoms in Post-Menopausal Women; Results of a Randomised, Double-Blind, Placebo-Controlled, Dose-Finding Study (SWITCH-1)

James A. Simon, Richard A. Anderson, Elizabeth Ballantyne et al. · Journal of the Endocrine Society · 2020 · 13 citations · Full text

Medicine, Endocrinology, Pharmacology +16